logo-loader
viewOpen Orphan PLC

Open Orphan makes further progress with Genomic Health DataBANK platform

It has has signed five unnamed pharmaceutical and biotechnology companies as early adopters of the new product

Open Orphan Plc -
Collaborations are also underway with patient advocacy groups to make sure potential users are aware of the service

Open Orphan Plc (LON:ORPH) said it has signed five unnamed pharmaceutical and biotechnology companies as early adopters of its Genomic Health DataBANK platform that is planned for launch in the first quarter of next year.

They will ensure it is “fit-for-purpose” ahead of the first patient upload.

This builds on the previously-announced collaboration with Empiric Logic, which is working with Open Orphan to complete the product.

"We are very excited to be working with these leading pharmaceutical and biotechnology companies on our market leading DataBANK. The Genomic Health DataBANK, which makes extensive use of AI tools, is an innovative research tool for pharmaceutical companies, and we are excited by its potential when launched in early 2020,” said Open Orphan chief commercial officer, Maurice Treacy.

“We believe the DataBANK can ignite research for new diagnostic tools and therapeutic products for rare disease patients."

Collaborations are also underway with patient advocacy groups to make sure potential users are aware of the service.

Open Orphan has two data-driven digital platforms: The aforementioned Genomic Health DataBANK, which is creating a rare disease database, and its Virtual Rep product, which enables pharmaceutical companies to engage key opinion leaders and doctors.

Quick facts: Open Orphan PLC

Price: 6.58 GBX

AIM:ORPH
Market: AIM
Market Cap: £29.32 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Open Orphan confirms hVIVO deal is done

Cathal Friel, CEO of Open Orphan announces that the hVIVO deal is finally in the bag and tells Proactive London what the timeline for shareholders now looks like. News here on the Genomic Database and how Friel expects hVIVO to make a profit. Confirmation too on the slight musical chairs within...

1 week ago

RNS

Holding(s) in Company

10 hours, 10 minutes ago

Holding(s) in Company

10 hours, 20 minutes ago

Holding(s) in Company

1 day, 6 hours ago

Holding(s) in Company

2 days, 3 hours ago

Euronext Growth Dublin Notice

2 days, 12 hours ago

Offer Wholly Unconditional

5 days, 13 hours ago

2 min read